RBC Europe’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q2
$1.83M Sell
5,648
-2,772
-33% -$832K 0.09% 84
2022
Q1
$2.41M Buy
8,420
+400
+5% +$103K 0.1% 79
2021
Q4
$2.21M Sell
8,020
-54,221
-87% -$13.7M 0.1% 78
2021
Q3
$14.4M Buy
62,241
+58
+0.1% +$14.3K 0.59% 32
2021
Q2
$14.3M Buy
62,183
+135
+0.2% +$27.1K 0.65% 31
2021
Q1
$11.6M Sell
62,048
-60
-0.1% -$11.7K 0.62% 30
2020
Q4
$10.5M Hold
62,108
0.6% 30
2020
Q3
$9.19M Sell
62,108
-1,810
-3% -$280K 0.61% 30
2020
Q2
$10.5M Sell
63,918
-455
-0.7% -$69.8K 0.81% 21
2020
Q1
$8.93M Buy
64,373
+52,321
+434% +$7.19M 0.89% 21
2019
Q4
$1.58M Hold
12,052
0.14% 93
2019
Q3
$1.35M Sell
12,052
-220
-2% -$24.5K 0.13% 99
2019
Q2
$1.36M Sell
12,272
-269
-2% -$31.7K 0.14% 100
2019
Q1
$1.63M Sell
12,541
-642
-5% -$78.1K 0.18% 91
2018
Q4
$1.53M Buy
13,183
+180
+1% +$20.1K 0.2% 85
2018
Q3
$1.4M Sell
13,003
-570
-4% -$57K 0.15% 99
2018
Q2
$1.16M Hold
13,573
0.14% 104
2018
Q1
$1.05M Buy
13,573
+303
+2% +$24.4K 0.13% 110
2017
Q4
$1.12M Sell
13,270
-166
-1% -$14.1K 0.14% 104
2017
Q3
$1.15M Buy
+13,436
New +$1.1M 0.15% 100

Other funds holding LLY

RBC Europe's LLY Position: Q2 2022 in Review

RBC Europe reduced its Eli Lilly (LLY) stake by 33% in Q2 2022, selling an estimated $832K and leaving 5,648 shares worth $1.83M. The position accounts for 0.09% of the portfolio, ranked #84.

RBC Europe first reported a position in LLY in Q3 2017 and has held it in 20 quarters since. The position peaked at $14.4M in Q3 2021. 2,446 funds tracked by Wall St. Rank hold LLY as of Q2 2022.

  • RBC Europe held 5,648 shares of Eli Lilly worth $1.83M as of Q2 2022.
  • RBC Europe sold 2,772 Eli Lilly shares in Q2 2022, an estimated $832K.
  • Eli Lilly made up 0.09% of RBC Europe's portfolio in Q2 2022, its #84 holding.
  • RBC Europe first reported a position in Eli Lilly in Q3 2017 and has held it in 20 quarters since.
  • RBC Europe's Eli Lilly position peaked at $14.4M in Q3 2021.
  • 2,446 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2022.

Based on RBC Europe's 13F filing for Q2 2022, filed 14 Nov 2022.